The agency's announcement comes after Public Citizen, a public safety advocacy group, called on the agency to take the device off the market entirely. A petition filed by the group last year pointed to a recent study that found a 2.5-fold increase in stroke or death among patients with the Wingspan stent system, compared with patients taking blood-thinning medication alone.
In its announcement Wednesday, the FDA acknowledged those risks but said the device may still be beneficial to patients who have not responded to other therapies.
"After careful consideration of available safety information, the FDA believes this device should remain available for this specific subgroup of patients who have exhausted other options," said Dr. Jeffrey Shuren, director of the FDA's center for devices.
Public Citizen criticized the FDA's decision, saying the stent would likely still be given to patients fitting the device's old criterion. Although the FDA sets labeling for drugs and devices, doctors are free to use them as they see fit.
"Even for those patients getting the device according to the new labeling, it is not clear that the benefits outweigh the risks," said Dr. Sidney Wolfe, who directs Public Citizen's health research group.
Wingspan consists of a small, mesh metal tube that is braced into place via inflatable tube, promoting blood flow through the arteries to the brain. The stent was approved under a special program that grants speedy approval to devices for rare diseases and conditions that affect fewer than 4,000 people in the U.S. each year. The device was first developed by Boston Scientific Corp. and later sold to Kalamazoo, Mich.-based Stryker Corp.
Shares of Stryker fell 1 cent to close at $52.99.